adenosine 2-aminosuccinic acid- 2- (6- amino- 9H- purin- 9- yl)- 5- (hydroxymethyl)tetrahydrofuran- 3,4- diol

01/01/2012 - "The aim of this study is to know how IFC-305 compound induces proliferation of the liver during reversion of cirrhosis. "
01/01/2018 - "These results contribute to understand the function of the IFC-305, which modulates the immune response in the Wistar rat model of CCl4-induced cirrhosis and support the hepatic protective action through an anti-inflammatory effect, mainly mediated by Kupffer cells."
01/01/2018 - "These results reveal one of the mechanisms of action of IFC-305 and suggest a possible therapeutic function in cirrhosis. "
01/01/2018 - "Therefore, Wistar rats were CCl4 treated and a sub-group received IFC-305 to reverse fibrosis. "
02/01/2010 - "Thus, understanding of the anti-cirrhotic effect of IFC305 might have therapeutical potential in patients with cirrhosis."

01/01/2023 - "An adenosine derivative (IFC-305) has been shown to exert protective effects in models of liver damage as well as on elements involved in central metabolism; therefore, here, we evaluated the effect of IFC-305 in an experimental model of metabolic syndrome in rats induced by a high-fat diet and 10% sucrose in drinking water for 18 weeks. "

09/01/2023 - "This study showed that IFC-305 can inhibit liver fibrosis establishment by regulating the immune response during CCl4-induced damage. "
09/01/2023 - "The immunomodulatory action of IFC-305 supports its use as a potential therapeutic strategy for preventing liver fibrosis."
02/01/2010 - "The present study shows that IFC305 reverses liver fibrosis through modulation of adipogenic and fibrosis-related genes and by ameliorating hepatic function. "
09/01/2023 - "CCl4-induced liver fibrosis and inflammation were significantly reduced in rats treated with IFC-305 at 6 and 8 weeks. "
02/01/2010 - "This study investigates the reversing capacity of an adenosine derivative compound (IFC305) on a rat model of liver cirrhosis and gene expression changes associated with it. "

01/01/2017 - "Conclusion: This study supports IFC-305 as a potential hepatocellular carcinoma treatment or as an adjuvant in chemotherapy."
01/01/2020 - "Role of autophagy in the chemopreventive effect of the IFC-305 compound in the sequential model of cirrhosis-hepatocellular carcinoma in the rat and in vitro."
01/01/2017 - "Functional, Metabolic, and Dynamic Mitochondrial Changes in the Rat Cirrhosis-Hepatocellular Carcinoma Model and the Protective Effect of IFC-305."
01/01/2017 - "Methods: Experimental groups of rats were formed to induce cirrhosis-hepatocellular carcinoma and to assess the IFC-305 effect during cancer development and progression through the evaluation of functional, metabolic, and dynamic mitochondrial parameters. "
01/01/2017 - "Aim: In this work we aimed to evaluate the functional, metabolic, and dynamic mitochondrial alterations in the sequential model of cirrhosis-hepatocellular carcinoma induced by diethylnitrosamine in rats and the possible beneficial effect of IFC-305. "

09/01/2023 - "CCl4-induced liver fibrosis and inflammation were significantly reduced in rats treated with IFC-305 at 6 and 8 weeks. "
01/01/2018 - "Inflammation is regulated by the adenosine derivative molecule, IFC-305, during reversion of cirrhosis in a CCl4 rat model."
01/01/2018 - "The IFC-305 compound, an adenosine derivative salt, reverses the cirrhosis in this model, suggesting that immune mechanisms related to inflammation should be explored. "